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Key points summary 27 
 Uterine artery vasodilatation is a key mechanism for increasing utero-placental 28 
blood flow and fetal nutrient supply. 29 
 Since the pioneering work of Joseph Barcroft, the natural laboratory of high 30 
altitude has been used to study the mechanisms regulating uterine artery blood 31 
supply and fetal growth. 32 
 Genes near the metabolic sensor, adenosine monophosphate-activated protein 33 
kinase (AMPK) have been implicated in genetic protection from high altitude-34 
associated fetal growth restriction. 35 
 We show that AMPK is present in utero-placental tissues, has vasodilator effects 36 
in murine uterine arteries, and that exposure to chronic hypoxia sufficient to 37 
decrease fetal growth increases the vasodilator actions of AMPK in opposing 38 
phenylephrine-induced vasoconstriction. 39 
 These results point to AMPK as being a key link between maternal vascular 40 
responses to pregnancy and fetal growth.  Manipulation of AMPK may be a novel 41 
mechanism for developing new therapies in pregnancies complicated by chronic 42 
hypoxia.  43 
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Abstract 45 
Genes near PRKAA1 (adenosine monophosphate-activated protein kinase 46 
[AMPK] alpha-1) have been implicated in the greater uterine artery (UtA) blood flow and 47 
relative protection from fetal growth restriction seen in altitude-adapted, Andean 48 
populations. AMPK activation vasodilates multiple vessels but whether AMPK is present 49 
in UtA or placental tissue and influences UtA vasoreactivity during normal or hypoxic 50 
pregnancy remains unknown. We studied isolated UtA and placenta from near-term 51 
C57BL6/J mice housed in normoxia (n=8) or hypoxia (10% FiO2, n=7-9) from day 14-19, 52 
and placentas from non-labouring sea level (n=3) or 3100 m (n=3) women. Hypoxia 53 
increased AMPK immunostaining in near-term murine UtA and placental tissue. RT-54 
PCR products for AMPK alpha-1 and alpha-2 isoforms and LKB1 (the upstream kinase 55 
activating AMPK) were present in murine and human placenta, and hypoxia increased 56 
LKB1, AMPK alpha-1 and alpha-2 expression in the high- compared with low-altitude 57 
human placentas. Pharmacological AMPK activation by A769662 caused phenylephrine 58 
pre-constricted UtA from normoxic or hypoxic pregnant mice to dilate and this dilatation 59 
was partially reversed by the NOS inhibitor L-NAME. Hypoxic pregnancy sufficient to 60 
restrict fetal growth markedly augmented the UtA vasodilator effect of AMPK activation 61 
in opposition to PE constriction as the result of both NO-dependent and -independent 62 
mechanisms. We concluded that AMPK is activated during hypoxic pregnancy, and that 63 
AMPK activation vasodilates the UtA, especially in hypoxic pregnancy. AMPK activation 64 
may be playing an adaptive role by limiting cellular energy depletion and helping to 65 
maintain utero-placental blood flow in hypoxic pregnancy.  66 
Keywords: fetal growth restriction, high-altitude adaptation, nitric oxide, utero-placental 67 
blood flow, phenylephrine  68 
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Introduction 70 
Pioneering studies of Joseph Barcroft and his students drew attention to the 71 
value of high altitude as a natural laboratory for understanding the mechanisms by 72 
which intrauterine hypoxia reduces fetal growth (Barcroft, 1933; Barron et al., 1964). A 73 
key determinant of fetal growth is the pregnancy rise in uterine artery (UtA) blood flow, 74 
which is due, in turn, to profound changes in multiple physiological systems (Gant & 75 
Worley, 1989). Among the greatest are the structural remodelling and alterations in 76 
vasoreactivity of the uterine vasculature that result in approximately 20% of the 77 
maternal cardiac output being directed to the utero-placental circulation by term (Osol & 78 
Moore, 2014). Isolated vessel studies in experimental animals show that chronic 79 
hypoxia is associated with a decreased vasodilator response to flow and to 80 
pharmacological agonists in the main UtA and downstream vessels (White et al., 2000; 81 
Mateev et al., 2003; Xiao et al., 2010), which may, in turn, contribute to the reduced UtA 82 
blood flow and altitude-associated fetal growth restriction seen in high-altitude 83 
newcomers (Zamudio et al., 1995; Julian et al., 2008). Multigenerational highland 84 
residents (Andeans and Tibetans) are relatively protected from altitude-associated 85 
reductions in fetal growth and have a greater pregnancy rise in UtA blood flow 86 
compared with altitude newcomers (Moore et al., 1998; Giussani et al., 2001; Moore et 87 
al., 2001; Chen et al., 2002; Julian et al., 2007; Julian et al., 2009; Soria et al., 2013). 88 
Such protection appears due, in part, to genetic factors given that it is proportional to 89 
the degree of highland ancestry and is not the result of the woman’s own duration of 90 
residence at high altitude (Bennett et al., 2008; Julian et al., 2011; Soria et al., 2013).   91 
Identifying the genes and signalling pathways involved in protecting native 92 
highlanders presents a novel means for addressing the mechanisms by which 93 
intrauterine hypoxia influences fetal growth. Several gene regions have been acted 94 
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upon by natural selection in long-resident populations (Bigham et al., 2009; Beall et al., 95 
2010; Bigham et al., 2010; Simonson et al., 2010; Yi et al., 2010; Alkorta-Aranburu et 96 
al., 2012). In Andeans, prominent among these are single nucleotide polymorphisms 97 
(SNPs) near PRKAA1 (adenosine monophosphate-activated protein kinase [AMPK] 98 
alpha-1) (Bigham et al., 2009; Bigham et al., 2010). Further, the AMPK alpha-1 variants 99 
more common in Andeans are positively associated with infant birth weight as well as 100 
with key determinants of fetal growth, namely the pregnancy-associated increase in UtA 101 
diameter and the expression patterns of genes in metabolic pathways proposed to play 102 
a role in altitude-associated fetal growth restriction (Yung et al., 2012; Bigham et al., 103 
2014).   104 
AMPK is a ubiquitously expressed enzyme in eukaryotes, that is stimulated by 105 
stresses that deplete cellular ATP and thus serves as a metabolic sensor for matching 106 
tissue energy demand with supply (Hardie et al., 2012). It is comprised of three subunits 107 
(alpha, beta, gamma), each of which has multiple isoforms whose expression levels 108 
vary by tissue type (Viollet et al., 2010). The alpha-1 and alpha-2 isoforms are the 109 
catalytic subunits and contain the Thr-172 site where AMPK is activated more than 100-110 
fold via phosphorylation by LKB1 and other upstream kinases (Evans et al., 2009; 111 
Viollet et al., 2009). In skeletal muscle AMPK activation promotes glucose uptake and 112 
mitochondrial biogenesis, and decreases energy demand by inhibiting the mechanistic 113 
target of rapamycin (mTOR) and switching on various catabolic enzymes (Hardie, 114 
2011). More recently, AMPK activation has been recognized to have vascular effects, 115 
acting to stimulate endothelial nitric oxide (NO) production (Wang & Proud, 2006) as 116 
well as to regulate smooth muscle function directly (Goirand et al., 2007). Underscoring 117 
its importance under conditions of hypoxia, AMPK activation has been implicated in the 118 
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aetiology of early-onset pre-eclampsia (Yung et al., 2014), cardiorespiratory responses 119 
to hypoxia (Evans, 2006), and hypoxic pulmonary vasoconstriction (Evans et al., 2005).   120 
It is unknown whether AMPK activation influences UtA vasoreactivity during 121 
pregnancy and, if so, whether such effects are altered by exposure to hypoxia. We used 122 
a broad-ranging approach to address such questions in which human as well as 123 
experimental-animal tissues were studied using multiple methods. Specifically, we 124 
hypothesized that AMPK was present in UtA and placental tissue and that its 125 
expression was increased during pregnancy by exposure to hypoxia as detected using 126 
immunohistochemistry in mice and quantitative RT-PCR in previously-collected human 127 
tissues. We further hypothesized that AMPK activation prompted UtA vasodilation 128 
and/or altered vasoconstrictor sensitivity to phenylephrine (PE) in vessels isolated from 129 
near-term mice, and that such effects were altered by exposure to hypoxia. To test 130 
these hypotheses we used the pharmacological AMPK agonist A769662 and compared 131 
UtA vasodilator and vasoconstrictor responses in vessels isolated from the normoxic vs. 132 
hypoxic animals. Finally, we treated vessels with the NOS inhibitor NG-nitro-L-arginine 133 
methyl ester (L-NAME) to determine the contribution of NO-dependent and  134 
-independent mechanisms to the effects of AMPK activation observed. We considered 135 
that such studies would improve our understanding of the mechanisms regulating 136 
maternal vascular responses to pregnancy and fetal growth under conditions of chronic 137 
hypoxia.  138 
 139 
Methods 140 
Ethical Approval. All mouse experiments were carried out using procedures 141 
consistent with the UK Animals Scientific Procedures Act 1986 and approved by the 142 
Local Ethics Review Committee of the University of Cambridge. Placentas were 143 
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collected from human subjects who provided written informed consent to procedures 144 
approved by the University of Colorado Multiple Institutional Review Board (COMIRB, 145 
Aurora, CO, USA), the University College Hospital London (London, UK), and the 146 
Cambridge Local Research Ethics Committee. 147 
Samples and Protocols. Female C57BL6/J mice were placed with males 148 
overnight. The presence of a copulatory plug the following morning was taken to 149 
indicate day one of pregnancy. Pregnant mice (n=31) were housed in groups of two or 150 
three in rooms with 21% O2, 12 hr light-dark cycles and controlled temperature (21°C) 151 
and humidity (60%). They had ad libitum access to food (Rat and Mouse No. 3 152 
Breeding, Special Diet Services, Witham, UK). At day 14 of pregnancy (term is ~ 21 153 
days), animals were randomly assigned to normoxic or hypoxic (10% O2) treatment 154 
groups. Hypoxia was achieved by placing the animals in a chamber containing a PVC 155 
isolator (PFI plastics Ltd) and a N2 generator (N2MID60, Domnick Hunter Ltd, UK) so as 156 
to control the percent O2 within the chamber without changing the CO2 levels by altering 157 
the inflows of air and N2. O2 levels were monitored using an O2 analyser (ICA, UK) and 158 
CO2 levels by a portable CO2 analyser that was calibrated daily (The Electronic 159 
Workshop, Department of Physiology, Development and Neuroscience, University of 160 
Cambridge). Normoxic animals were housed in the same room that contained the 161 
chambers. Maternal weight, food and water intake were monitored daily.  This was 162 
achieved in the hypoxic group via a sealed transfer box that could be opened briefly 163 
without altering O2 levels within the main chamber.  164 
On day 19 of pregnancy mice were euthanized by cervical dislocation. The 165 
uterus was dissected, the numbers of viable fetuses and fetal reabsorptions counted, 166 
fetal and placental weights recorded, and fetal biometry taken. Both UtA were removed, 167 
with one being used for myography and the other for immunohistochemistry. In 168 
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approximately half the normoxic and hypoxic animals, one placenta whose weight was 169 
closest to the litter mean was prepared for immunohistochemistry. 170 
Samples from human placentas were obtained from term, non-labouring women 171 
residing either at sea level (n=3) or high altitude (3100 m, n=3) as described previously 172 
(Yung et al., 2012).   173 
Immunohistochemistry. The murine uterine vessels were placed in ice cold PBS, 174 
cleared of adipose tissues and the uterine horn using a dissecting microscope (Leica, 175 
Germany), and fixed in 4% paraformaldehyde. The main UtA together with its 1st and 176 
2nd order branches was divided into 2-3 longitudinal segments, embedded in a single 177 
paraffin block, and sectioned. Whole placentas were washed with PBS, fixed in 4% 178 
paraformaldehyde, embedded in paraffin, and sectioned. Paraffin-embedded sections 179 
were de-waxed, washed, prepared for antigen retrieval using 0.01 M citric buffer (pH 180 
6.0), and incubated overnight using either primary antibody (phospho-AMPKα [Thr172] 181 
[40H9] rabbit) from Cell Signalling Technology (Hitchin, UK) diluted in 5% GS/HS in 182 
TBS or vehicle alone. The following day, the secondary antibody (anti-rabbit IgG, diluted 183 
1:200 in 5% GS/HS) was applied, incubated for 1 hr, developed for staining using DAB 184 
and counterstained with hematoxylin. The slides were scanned using a Nanozoomer 185 
(Hamamatsu Photonics, Welwyn Garden City, UK), saved as high-resolution files, and 186 
images quantified using IPLAb software (v6.0, Scanalytics, Fairfax, VA). DAB-positive 187 
areas were selected and segmented in a region of interest based on a selective 188 
distribution of saturation and hue values that matched the color of the DAB reactive 189 
product and the pattern of staining of the image. Segmented overlays representing the 190 
selected pixels of DAB staining were selected in individual UtA and the labyrinthine and 191 
junctional zones (separately), quantified and expressed as the percent area of positive 192 
DAB staining per area of tissue examined. 193 
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Quantitative RT-PCR. RNA from mouse (n=3) or human (n=6) placental tissue 194 
was extracted using the miRNeasy Mini Kit from Qiagen (Manchester, UK) following the 195 
manufacturer’s guidelines, and the concentration determined using a Nanodrop 1000 196 
spectrophotometer (Thermo Scientific, Hemel Hempstead, UK). cDNA synthesis was 197 
carried out using the Transcriptor High Fidelity cDNA synthesis Kit (Roche, UK) 198 
following manufacturer instructions. For qPCR analysis, 2.5 µl of cDNA in RNase free 199 
water was made up to 25 µl with FastStart Universal SYBR Green Master (ROX, 12.5 200 
µl, Roche), Ultra Pure Water (8 µl, SIGMA, UK) and forward and reverse primers for 201 
LKB1, AMPK alpha-1 and alpha-2 (Qiagen, UK). The sample was then centrifuged and 202 
25 µl added to a MicroAmpTM Fast Optical 96-Well Reaction Plate (Greiner Bio-One, 203 
Stonehouse UK), the reaction plate sealed with an optical adhesive cover (Applied 204 
Biosystems, Warrington UK) and the plate centrifuged. The reaction was then run on a 205 
sequence detection system (Applied Biosystems) using AmpliTaq Fast DNA 206 
Polymerase with a 2 min initial step at 50oC followed by a 10 min step at 95oC, a 15 sec 207 
step at 95oC (repeated 40 times) followed by a dissociation stage with a 15 sec step at 208 
95oC, and followed by a 20 sec at 60oC and a 15 sec step at 95oC. Negative controls 209 
included tissue aspirants for which no reverse transcriptase was added, and aspiration 210 
of extracellular medium and PCR controls. None of the controls produced any 211 
detectable amplicon, ruling out genomic or other contamination.  212 
Myography. The murine uterine vasculature was dissected and pinned out in a 213 
dish of ice-cold Krebs solution (in mmol/L, all reagents from Sigma UK unless specified 214 
otherwise: NaCl 118.5, NaHCO3 25, KCl 4.75, MgSO4.7H2O 1.2, KH2PO4 1.2, CaCl2 215 
2.5, D-glucose 11.1). Using a bifocal dissecting microscope (Brunel Microscopes Ltd., 216 
UK), first-order 2 mm in length UtA segments were dissected and cleared of any 217 
connective or adipose tissue. The vessel segments were then mounted in a four-218 
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chamber, small-vessel wire myograph (Multi Wire Myograph System 620M, DMT, 219 
Denmark) by threading two wires 40 µm in diameter through the vessel lumen and 220 
attaching one to a pressure transducer and the other to a micrometer as previously 221 
described (Pulgar et al., 2011; Giussani et al., 2012). The chamber was continually 222 
gassed with 5% CO2 and 95% O2 to maintain a physiological pH, and gradually heated 223 
to 37°C. Throughout the investigation, the Krebs solution was refreshed every 20 min, 224 
and the vessels allowed to re-equilibrate for at least 20 min between experiments. 225 
UtA were normalised to 0.9 of L13.3 kPa, and allowed to equilibrate for 20 min. 226 
Following normalisation a ‘wake up’ protocol was performed consisting of exposure of 227 
the vessels to a high concentration of potassium (KCl, 125 mmol/L). Vessel viability was 228 
verified by a positive constrictor response to phenylephrine (PE, 1x10-4 M) and a 229 
positive relaxant response to acetylcholine (ACH, 1x10-10 M to 1x10-4 M). Two vessels 230 
from each animal were pre-constricted with a dose of PE determined to produce 70% of 231 
the maximal constriction to PE for each vessel. The sub-maximally pre-constricted 232 
vessels were then relaxed by addition of the AMPK agonist A769662 (Tocris, USA) 233 
dissolved in DMSO in increasing concentrations (1x10-6 M to 1x10-4 M) at 10-min 234 
intervals, and the results from the two vessels per animal averaged. We chose A769662 235 
because, unlike 5-amino-1-beta-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) or 236 
metformin, it activates AMPK directly, and not other enzymes that are responsive to 237 
AMP levels (Goransson et al., 2007). Another advantage is that A769662, unlike 238 
AICAR, is not taken up by the adenosine transporter and therefore does not lead to the 239 
accumulation of adenosine outside cells or necessitate the use of an adenosine 240 
antagonist (Goransson et al., 2007). A third and fourth vessel segment from each 241 
animal was also tested using increasing doses of PE (1x10-9 M – 1x10-4 M), with this 242 
then being repeated following 20 min incubation with A769662 (1x10-4 M) and finally 243 
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repeated a third time following incubation with A769662 (1x10-4 M) plus the NOS 244 
inhibitor L-NAME (1x10-5 M). The finding that the third curve was consistently larger 245 
than the second provided reassurance that the response of the vessels was not 246 
deteriorating over time. Studies were completed in vessels from a total of 17 animals.  247 
Data and Statistical Analyses. The contractile response to PE was expressed as 248 
a percentage of the maximal constriction produced by KCl (% Kmax). The curves were 249 
fitted with the best-fit line for describing the response to a given agonist. The negative 250 
logarithm to base 10 of the dose at which vessels were 50% maximally-constricted to 251 
PE (pD2) was used as an index of vascular sensitivity, and the area under the curve 252 
(AUC) was calculated to assess overall reactivity using Prism v6.0 (GraphPad Software, 253 
La Jolla CA). Single values were compared between normoxic and hypoxic groups 254 
using unpaired t-tests. Differences in immunostaining or mRNA expression between 255 
normoxic and hypoxic groups were assessed using one-way ANOVA with Student 256 
Neuman Keuls post hoc test. The effects of AMPK activation on PE-induced constriction 257 
were assessed using two-way ANOVA with Tukey post hoc test (Sigma Stat, 258 
Buckinghamshire, UK). Data are presented as the mean ± standard error of the mean 259 
(S.E.M.).  Significance was accepted when the two-tailed p<0.05 and reported as trends 260 
when 0.05<p<0.10. 261 
 262 
Results 263 
Maternal and fetal characteristics. Murine maternal body weights were similar at 264 
days 1 and 14, but reduced at day 19 in the hypoxic compared with normoxic groups 265 
(Table 1). Litter size was not reduced in the hypoxic group although there was a trend 266 
for a greater number of reabsorptions. Fetuses from hypoxic pregnancies weighed less 267 
but placental weights were similar to those seen in the normoxic group. Fetuses from 268 
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the hypoxic compared with the normoxic group had smaller crown-rump lengths, 269 
biparietal diameters (BPD) and a greater BPD to body weight ratio, indicating 270 
asymmetric growth restriction (Table 1).  271 
Placental and birth weights were similar for the non-labouring, sea-level or high-272 
altitude women (Table 1), although birth weight was reduced at high altitude in the 273 
larger group of subjects from which these data were derived (Yung et al., 2012) 274 
Immunohistochemistry. The uterine vessels from normoxic mice demonstrated 275 
staining for phosphorylated (activated) AMPK in arteries of varying size. The hypoxic 276 
compared with normoxic animals had greater staining intensity with primary antibody 277 
(11.0% vs. 22.0% respectively, p<0.0001) whereas the staining intensity did not differ in 278 
the vessels from normoxic animals with and without antibody (p=0.12), indicating 279 
minimal AMPK expression (Figure 1, left hand panels). Phosphorylated AMPK was also 280 
present in all regions of the mouse placenta (Figure 1, right hand panels). Whereas 281 
staining intensity did not differ between the JZ and LZ of the placenta from normoxic 282 
animals (p=NS), hypoxic exposure markedly increased LZ relative to JZ staining 283 
(p<0.0001). 284 
Quantitative RT-PCR. Results from quantitative RT-PCR assays showed that 285 
mRNA for LKB1, AMPK alpha-1, and AMPK alpha-2 (as a % of -actin) were present in 286 
human and mouse placental tissue. Levels of RT-PCR products for LKB1 and both 287 
AMPK catalytic isoforms were greater in the tissues from the high-altitude compared 288 
with sea-level human placentas (Figure 2, top panel). In sea-level mouse placentas, 289 
AMPK alpha-2 levels were higher in the labyrinthine than junctional zones (Figure 2, 290 
bottom panel).  291 
Myography. The internal circumference of the isolated UtA at the time of study 292 
was similar in the normoxic and hypoxic murine groups (Table 1). There was no 293 
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difference in the maximal contraction to KCl or PE, or the contractile sensitivity to PE as 294 
measured by the pD2 (Table 1) or the relaxation response to ACH (10
-10 M to 10-4 M, 295 
data not shown).  296 
A769662, an AMPK agonist, caused complete, concentration-dependent 297 
relaxation in the PE pre-constricted UtA and that relaxation was similar in the normoxic 298 
and hypoxic mice (Figure 4 3A). Inhibition of NOS by incubation with L-NAME reduced 299 
the relaxation response to A769662 by 30% but did not fully reverse it, indicating that 300 
70% of the effect was NO-independent in both the normoxic and hypoxic groups (Figure 301 
3B).  302 
Incubation with the AMPK agonist A769662 reduced UtA contractile sensitivity to 303 
PE in both the normoxic and hypoxic mice as demonstrated by the rightward shifts in 304 
the contractile concentration-response curves (Figure 4A-B), with the change due to 305 
A769662 being greater in the hypoxic than normoxic groups (Figure 5 4C). Treatment of 306 
the vessel with L-NAME increased contractile sensitivity to PE in vessels from normoxic 307 
or hypoxic mice (both p<0.05), indicating that a portion of A769662’s vasodilator effect 308 
was due to increased NO production or activity. However, L-NAME treatment did not 309 
fully reverse the effect of A769662, indicating that there was a NO-independent 310 
contribution as well. Moreover the NO-independent component was principally 311 
responsible for the greater vasodilator effect of AMPK activation seen in the vessels 312 
from hypoxic than normoxic animals (Figure 5 4D). 313 
 314 
Discussion  315 
Our principal findings were that AMPK was present in uterine arteries from near-316 
term mice as well as in mouse and human placental tissue, and that its AMPK 317 
expression was increased by hypoxia as judged by immunohistochemistry and mRNA 318 
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expression. Consistent with the possibility that the LKB1-AMPK signalling pathway 319 
influenced vascular reactivity, we found that pharmacological activation of AMPK 320 
caused PE-preconstricted UtA from pregnant mice to relax due to both NO-dependent 321 
and -independent mechanisms. While the vasodilator effect of AMPK activation was 322 
similar in UtA isolated from normoxic or hypoxic mice, AMPK activation more markedly 323 
opposed PE-induced constriction in the UtA from the hypoxic than the normoxic mice 324 
and this was due to NO-dependent and largely NO-independent mechanisms. We 325 
therefore concluded that AMPK activation dilates uterine arteries, particularly in 326 
response to PE-induced vasoconstriction, and that this latter effect is enhanced by 327 
hypoxic pregnancy. 328 
AMPK activation in non-pregnant animals has chiefly been studied for its 329 
metabolic effects. Drugs such as metformin, which is widely prescribed for lowering 330 
glucose levels in individuals with type 2 diabetes, decrease hepatic glucose production 331 
by mildly inhibiting the mitochondrial respiratory chain complex I, which in turn activates 332 
AMPK (Viollet et al., 2012). In skeletal muscle, AMPK activation promotes glucose 333 
uptake and mitochondrial biogenesis, and decreases energy demand by inhibiting the 334 
mechanistic target of rapamycin (mTOR) or by switching on the expression of various 335 
catabolic enzymes (Hardie, 2011). More recently it has been recognized that AMPK 336 
activation also has vascular effects. Vessels express AMPK alpha-1 and alpha-2 337 
isoforms; alpha-1 predominates in endothelial cells and both are present in vascular 338 
smooth muscle with their relative predominance varying by tissue type (Evans et al., 339 
2005; Goirand et al., 2007; Matsumoto et al., 2008).  AMPK activation has been shown 340 
to improve cardiac function in a rat model of chronic heart failure (Wang et al., 2011); to 341 
help initiate hypoxic pulmonary vasoconstriction (Evans et al., 2005); and to augment 342 
acetylcholine-induced relaxation in pre-constricted isolated thoracic aorta, mesenteric or 343 
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resistance-sized cremaster arteries (Goirand et al., 2007; Ford & Rush, 2011). 344 
Importantly, the vascular effects of AMPK activation are not dependent on its metabolic 345 
effects (Bradley et al., 2010) or the accumulation of adenosine (Evans et al., 2005; 346 
Goirand et al., 2007; Bradley et al., 2010) but rather are due to both NO-dependent and 347 
NO-independent mechanisms; namely, increased eNOS activity and NO production 348 
(Viollet et al., 2010), decreased superoxide and vasoconstrictor prostanoid production 349 
(Matsumoto et al., 2008; Li et al., 2010), and direct actions in vascular smooth muscle 350 
(Goirand et al., 2007).  351 
Our data showing AMPK immunostaining in normoxic mouse uterine vessels and 352 
placenta tissue, and mRNA in murine and human placenta for both AMPK alpha 353 
isoforms and the upstream kinase responsible for activating AMPK, LKB1, in mouse 354 
and human placenta were consistent with prior reports showing that AMPK is expressed 355 
in placental tissue (Yung et al., 2012). This is, however, to the best of our knowledge 356 
the first report of its presence in murine uterine vessels during pregnancy. The UtA and 357 
other uterine vessels undergo profound changes during pregnancy, enlarging their 358 
diameters as the result of structural remodelling as well as increased vasodilator 359 
responses to flow, acetylcholine and other pharmacological agonists (reviewed in (Osol 360 
& Moore, 2014)). Such changes are attributable to effects of oestrogen and other 361 
pregnancy hormones serving to increase the production and/or activity of various 362 
vasodilators, including NO and large-conductance potassium channels (BKCA), rather 363 
than placentation per se since the changes begin before placentation is complete, occur 364 
even in ectopic pregnancy, and are present albeit to a lesser degree in pseudo-365 
pregnant animals (Burchell, 1967; Rosenfeld et al., 1996; van der Heijden et al., 2005; 366 
Collins et al., 2011; Hu et al., 2011). We also showed for the first time that uterine 367 
arteries are relaxed by AMPK activation, suggesting that activation of AMPK may be 368 
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another mechanism contributing to pregnancy vasodilatation. The vasorelaxant effects 369 
of AMPK activation were due, in part, to increased NO production or activity as shown 370 
by the effects of NOS inhibition but the major portion of its vasorelaxant effect remained 371 
following NOS inhibition, indicating that additional mechanisms are involved. One 372 
possibility is that AMPK activation reduced the production of vasoconstrictor 373 
prostanoids, similar to what has been reported in mesenteric arteries following 374 
metformin treatment in a rat model of type 2 diabetes (Matsumoto et al., 2008). Direct 375 
effects on vascular smooth muscle cells may also be involved via actions on the RhoA-376 
Rho associated protein kinase (Rock) pathway (Gayard et al., 2011) or via K+ channels 377 
given that AMPK activation affects multiple K+ channels (Andersen & Rasmussen, 378 
2012), including the BKCA and the ATP-sensitive potassium channel (KATP), previously 379 
implicated in uterine vascular responses to pregnancy and hypoxia (Zhu et al., 2013). 380 
Thus further study is required in both non-pregnant and pregnant animals to determine 381 
whether pregnancy influences the effects of AMPK activation on UtA vasoreactivity, and 382 
the endothelial as well as vascular smooth muscle mechanisms involved.  383 
Little is known about the effects of AMPK activation under conditions of hypoxia.  384 
Suggesting a beneficial role, Davidge and co-workers have shown that resveratrol, 385 
which works in part by activating AMPK (Hardie, 2011; Tennen et al., 2012), 386 
administered to the mother under conditions of severe hypoxia dramatically improved 387 
fetal survival and increased placental relative to fetal weight but not fetal growth per se 388 
(Bourque et al., 2012; Banek et al., 2013). Resveratrol treatment also increased UtA 389 
blood flow velocity and fetal weight in a catechol-O-methyltransferase knockout mouse 390 
model of fetal growth restriction, but vasodilator or vasoconstrictor responses of isolated 391 
UtA were unaffected (Poudel et al., 2013). Reseveratrol has also been shown to 392 
agument UtA blood flow during pregnancy in nonhuman primates (Roberts et al., 2014). 393 
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We found that hypoxia in late murine pregnancy sufficient to decrease fetal 394 
growth increased the intensity of AMPK immunostaining in the labyrinthine zone, which 395 
may be more sensitive to hypoxia given its rich blood supply in contrast to the relatively 396 
hypovascularized junctional zone (Dilworth & Sibley, 2013).  AMPK alpha-2 mRNA 397 
expression was also greater in the labyrinthine than the junctional zone of the mouse 398 
placenta, suggesting that it may be the isoform involved in the greater immunostaining 399 
but differences in primer efficiency prevent comparison of LKB1, AMPK alpha-1 and 400 
alpha-2 expression levels. In humans, the levels of RT-PCR products for both AMPK 401 
alpha subunits and LKB1 were greater in the placentas from high- vs. low-altitude 402 
residents, suggesting higher basal AMPK activity and / or increased capacity to respond 403 
to metabolic stress. However, while these same placentas showed evidence of 404 
endoplasmic reticulum (ER) stress and mTOR inhibition, the ratio of P-AMPK to total 405 
AMPK was not consistently elevated in the small number (n=3) of non-labouring 406 
placentas available for study (Yung et al., 2012). In pre-eclamptic women, the ratio of P-407 
AMPK to total AMPK protein levels was inversely correlated with gestational age, being 408 
highest in those with the earliest onset of disease, although not higher overall in early- 409 
(<34 wk) vs. late (> 34 wk) onset pre-eclamptic or normotensive women (Yung et al., 410 
2014). Thus, further studies in larger numbers of placentas are required to determine if 411 
AMPK is activated at high vs. low altitude in placental tissue.  412 
We were interested in the effect of AMPK activation on UtA vasoreactivity under 413 
conditions of hypoxia given our prior studies indicating that the gene region containing 414 
AMPK-1 has been acted upon by natural selection in Andean residents of high altitude 415 
and that the variants more common in Andeans were positively associated with birth 416 
weight, UtA diameter and alterations in the expression of genes in the mTOR pathway 417 
previously implicated in altitude-associated fetal growth restriction (Bigham et al., 2009; 418 
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Yung et al., 2012; Bigham et al., 2014). The increased intensity of immunostaining in 419 
the mouse uterine arteries suggested that hypoxia increased AMPK abundance. 420 
However, since the antibody employed detects both alpha-1 and alpha-2 isoforms, we 421 
were not able to determine which isoforms were present in the uterine vessels.  422 
Based on previous studies in pulmonary and uterine arteries, we expected that 423 
AMPK activation would have less vasodilator effect in the UtA isolated from the hypoxic 424 
vs. normoxic animals. In pulmonary arteries, AMPK activation under conditions of acute 425 
(< 60 min) hypoxia prompted vasoconstriction through mobilization of myocyte 426 
sarcoplasmic reticulum calcium stores via ryanodine receptors and the release of an 427 
endothelium-derived constrictor (Evans, 2006). Inhibitory effects of AMPK activation on 428 
BkCA channels have also been observed, and in a manner that is splice-variant specific 429 
(Wyatt et al., 2007; Ross et al., 2011). It is notable, therefore, that BkCA channels are 430 
inhibited in resistance-sized ovine uterine vessels and, in turn, reverse the normal 431 
pregnancy reduction in myogenic tone (Hu et al., 2012). Further, we have reported that 432 
hypoxia throughout pregnancy reduced the NO-dependent UtA vasodilator response to 433 
ACH and flow in isolated guinea pig UtA (White et al., 2000; Mateev et al., 2003). 434 
Therefore, our finding that pharmacological AMPK activation prompted similar 435 
concentration-dependent vasodilation in preconstricted UtA from normoxic and hypoxic 436 
animals was somewhat surprising. Since maximal contraction to PE tended (p=0.07) to 437 
be greater in the hypoxic than the normoxic group and in order to evaluate the 438 
relationship between AMPK activation and PE constriction more fully, we extended our 439 
study to examine the effect of AMPK activation on contractile sensitivity to PE. We 440 
found that AMPK activation markedly reduced UtA contractile sensitivity to PE in the 441 
UtA from the hypoxic compared with normoxic animals as demonstrated by a rightward 442 
shift in the contractile-response curves. The shift was greater in the vessels from the 443 
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hypoxic compared to normoxic animals, and was partly reversed by treatment with the 444 
NOS inhibitor L-NAME, suggesting a role for NO in opposing PE-induced of constriction. 445 
While we cannot rule out the possibility that hypoxic exposure increased NO sensitivity, 446 
this appeared unlikely given that the relaxation in response to ACH or A769662 was not 447 
greater in the UtA from the hypoxic compared to normoxic animals. In addition, even 448 
though the NO component was larger in the hypoxic group, the major portion of the 449 
greater reduction in contractile sensitivity to PE was NO-independent. We therefore 450 
concluded that greater AMPK activation under conditions of hypoxic pregnancy opposes 451 
PE-induced vasoconstriction, thus perhaps serving as a compensatory mechanism for 452 
maintaining uterine artery blood flow. Further studies are required for determining the 453 
mechanisms by which AMPK activation opposes PE-induced vasoconstriction and 454 
whether similar effects of AMPK activation are observed when hypoxia is present 455 
throughout gestation such as is the case in residents of high altitude.  456 
The strengths of our study were its broad-ranging design in which human as well 457 
as murine tissues were examined following exposure to normoxia and either shorter- or 458 
longer-term hypoxia. Further, multiple methods were used to evaluate the effects of 459 
AMPK activation and hypoxia; namely, immunohistochemistry, quantitative RT-PCR and 460 
myography. Our results, however, were limited by use of a single AMPK activator. While 461 
A769662, unlike other agonists, activates AMPK directly (Goransson et al., 2007), it too 462 
has indirect effects by, for example, inhibiting the sodium pump (Benziane et al., 2009). 463 
While we used only one agonist, our results were similar to those obtained using 464 
metformin, AICAR or exercise to activate AMPK, and thus suggested that the responses 465 
observed were the result of AMPK activation and not some other effect of the agonist 466 
employed (Goirand et al., 2007; Ford & Rush, 2011; Wang et al., 2011; Kroller-Schon et 467 
al., 2012) but additional studies using other agonists are required to confirm the 468 
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mechanisms of A769662 action. Further studies are also needed using western blot or 469 
other means to document AMPK activation, and using pair-fed animals to control for the 470 
lesser maternal weight gain seen during the period of hypoxic exposure in the present 471 
report. The possible effect of duration of hypoxic exposure also requires evaluation 472 
since the late-pregnancy onset employed here does not parallel the circumstances of 473 
residence at high altitude where hypoxia is present throughout gestation but, on the 474 
other hand, it does likely resemble that occurring with late-onset pre-eclampsia. 475 
In summary, AMPK is present in maternal uterine vessels as well as in placental 476 
tissues, and its abundance increased by short- as well as longer-term hypoxia as 477 
indicated by greater immunostaining in uterine vessels from pregnant mice and 478 
increased expression of both catalytic AMPK subunits in murine and human placenta. 479 
This is, to our knowledge, the first report that pharmacological AMPK activation prompts 480 
vasodilatation in UtA via both NO-dependent and -independent mechanisms and that 481 
exposure to chronic hypoxia sufficient to restrict fetal growth markedly augmented the 482 
ability of AMPK activation to oppose PE-induced vasoconstriction. Together with prior 483 
reports that genetic variation near AMPK is related to increased UtA blood flow and 484 
maintenance of fetal growth in high-altitude adapted Andeans, we speculate that AMPK 485 
activation may be helping to maintain utero-placental blood flow and thereby limit 486 
cellular energy depletion. In addition to its role as a metabolic sensor, AMPK may be a 487 
key link between maternal metabolic and cardiovascular responses to pregnancy and 488 
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Figure Captions 765 
Figure 1. Phosphorylated AMPK (brown staining) is present in uterine arteries (UtA) 766 
and placentas from normoxic mice and increased by hypoxia in the UtA and the 767 
placental labyrinthine (LZ) but not junctional (JZ) or the decidua (DEC) zones. For the 768 
placenta specimens, panels A and B are with and without AMPK antibody, respectively, 769 
at 5x and panels C and D are with AMPK antibody at 20x magnification. 770 
Figure 2. Upper Panel: mRNA for both AMPK alpha subunits and LKB1 are present at 771 
higher levels in human placentas from 3100 m vs. sea level. Lower Panel: Murine 772 
placentas also contain both AMPK alpha subunits and LKB1 at sea level, with 773 
expression levels for the alpha-2 subunit being greater in the labyrinthine than junctional 774 
zone. *=p<0.05, **=p<0.01, ****=p<0.0001. Data are mean + sem. 775 
Figure 3.  Panel A: Uterine arteries pre-constricted with a submaximal dose of PE from 776 
normoxic (n=5) and hypoxic (n=7) pregnant (day 19) mice relax in response to 777 
increasing concentrations of the AMPK agonist, A769662.  Panel B: The area under the 778 
curve (AUC), representing nitric oxide (NO)-dependent and -independent components 779 
did not differ in the normoxic and hypoxic groups.  Data are mean + sem. 780 
Figure 4.  Incubation with A769662 (1x10-4M, open circles, dotted lines) decreased 781 
contractile sensitivity to phenylephrine (PE) in UtA from both normoxic (panel A, n=8) 782 
and hypoxic (panel B, n=6-7) pregnant mice compared to values obtained contraction 783 
prior to incubation with A769662 (open circles, solid lines). This decrease was 784 
significant in both groups when expressed as the area under the curve (AUC) (panel C, 785 
p<0.05, two way ANOVA and post-hoc Tukey test). The AUC, representing the change 786 
in sensitivity to PE following incubation with A769662, was significantly greater in the 787 
hypoxic compared to the normoxic animals (panel C, p<0.05, unpaired t-test). Treatment 788 
with L-NAME (1x10-5 M, black boxes and dashed lines) decreased the contractile 789 
 29 
response to PE in A769662-treated vessels from normoxic (A) and hypoxic (B) pregnant 790 
mice, indicating a significant NO-dependent component (both p<0.05), but did not fully 791 
restore the contractile response. The contributions of both nitric oxide (NO)-dependent 792 
and -independent mechanisms as well as the total relaxation response were greater in 793 
the UtA from hypoxic compared with normoxic animals (panel D, p<0.05, unpaired t-794 
test). * = p<0.05. Data are mean + sem. 795 
 796 
Table 1.  Characteristics of the murine and human subjects.  
Variable Normoxic group Hypoxic group  P value 
Mice: 
Sample size 8 7-9  
Maternal body weight, gm                 day  1 26.4 ± 1.8 26.2 ± 0.8 0.89 
day 14 31.9 ± 2.2 31.8 ± 0.8 0.93 
day 19 37.4 ± 3.0 32.5 ± 1.1 0.046 
Litter size, n 6.0 ± 1.1 6.6 ± 0.4 0.59 
Reabsorptions, n 0.4 ± 0.2 1.2 ± 0.4 0.06 
Fetal weight, mg 1101.6 ± 11.0 816.2 ± 36.3 <0.0001 
Placental weight, mg 101.4 ± 7.5 95.5 ± 3.8 0.42 
Fetal crown-rump length, mm 18.2 ± 0.3 16.3 ± 0.4 0.002 
Fetal biparietal diameter, mm 5.4 ± 0.2 4.8 ± 0.1 0.03 
Fetal biparietal diameter/weight 0.49 ± 0.02 0.58 ± 0.02 0.006 
 847.6 ± 34.1 911.8 ± 39 0.21 
 1.08 ± 0.2 0.79 ± 0.1 0.20 
       124.8 ± 11.8 166.2 ± 17.5 0.07 
PD2, M 6.8 ± 0.29 7.1 ± 0.3 0.50 
PE+A769662 pD2 without L-NAME, M 5.7 ± 0.17 5.2 ± 0.1 0.045 
 PE+A769662 pD2 with L-NAME, M 5.9 ± 0.16 5.6 ± 0.2 0.32 
Human subjects:    
Sample size 3 3  
Placental weight, gm 670 + 118 530 + 35 0.33 
Infant birth weight, gm 3813 + 104 3263 + 502 0.58 
Infant gestational age, wk 39.2 ± 1.4 39.8 ± 1.7 0.78 
Values are means + sem.  Bolded p values are <0.05.   
Abbreviations: KCl = potassium chloride, L-NAME = Nω-Nitro-L-arginine methyl ester 
hydrochloride, PE = phenylephrine, pD2 = negative logarithm to base 10 of the EC50 or the 
dose at which 50% of the maximal contraction was achieved. 
 
